← Back to Search

PD-L1 t-haNK

PD-L1 t-haNK for Advanced Cancer

Phase 1
Waitlist Available
Research Sponsored by ImmunityBio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new treatment called PD-L1 t-haNK, which uses modified immune cells to fight advanced or spreading solid cancers. The goal is to see if it is safe and effective, and to find the best dose for future studies. PD-L1 t-haNK cells are a novel type of natural killer (NK) cell engineered to target and kill cancer cells expressing PD-L1.

Who is the study for?
Adults with advanced or metastatic solid cancers who've had at least one prior treatment can join this trial. They need a measurable tumor, must provide a recent biopsy, and be able to follow the study's schedule. People with autoimmune diseases, organ transplants, severe heart conditions, uncontrolled hypertension, certain infections like HIV or inadequate organ function are excluded.
What is being tested?
The trial is testing PD-L1 t-haNK for safety and early signs of effectiveness in treating various solid tumors. It aims to find the highest dose patients can tolerate without serious side effects and recommend a dose for future studies.
What are the potential side effects?
As this is an early-phase trial assessing PD-L1 t-haNK, specific side effects aren't listed but may include typical cancer therapy reactions such as fatigue, nausea, immune-related issues or infusion reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of DLTs and treatment-emergent adverse events
MTD or HTD and RP2D.
Secondary study objectives
Objective Response Rate (ORR)
Progression-free Survival (PFS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: PD-L1 t-hanK Dose Level 2Experimental Treatment1 Intervention
PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level 2 is 3 to 6.
Group II: PD-L1 t-haNk Dose -1a (if needed)Experimental Treatment1 Intervention
PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level -1a is 3 to six, if needed.
Group III: PD-L1 t-haNK Dose Level Recommended phase 2 dose (RP2D)Experimental Treatment1 Intervention
PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into RP2D is 4.
Group IV: PD-L1 t-haNK Dose Level 1Experimental Treatment1 Intervention
PD-L1 t-haNK will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level 1 is 3 to 6.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Immunotherapy, including treatments like PD-L1 t-haNK, works by enhancing the body's immune system to recognize and attack cancer cells. PD-L1 t-haNK involves engineered natural killer (NK) cells that target the PD-L1 protein on cancer cells, which often helps tumors evade immune detection. By blocking PD-L1, these therapies prevent cancer cells from suppressing the immune response, allowing NK cells and other immune components to effectively target and destroy the cancer. This approach is crucial for cancer patients as it offers a targeted treatment option that can potentially lead to better outcomes and fewer side effects compared to traditional therapies like chemotherapy.
Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.

Find a Location

Who is running the clinical trial?

ImmunityBio, Inc.Lead Sponsor
66 Previous Clinical Trials
4,749 Total Patients Enrolled

Media Library

PD-L1 t-haNK (PD-L1 t-haNK) Clinical Trial Eligibility Overview. Trial Name: NCT04050709 — Phase 1
Cancer Research Study Groups: PD-L1 t-hanK Dose Level 2, PD-L1 t-haNK Dose Level 1, PD-L1 t-haNk Dose -1a (if needed), PD-L1 t-haNK Dose Level Recommended phase 2 dose (RP2D)
Cancer Clinical Trial 2023: PD-L1 t-haNK Highlights & Side Effects. Trial Name: NCT04050709 — Phase 1
PD-L1 t-haNK (PD-L1 t-haNK) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04050709 — Phase 1
~3 spots leftby Dec 2025